These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 18634445)

  • 1. [Examination of the mechanism of ameliorating effect of alpha 1-blocker on storage symptoms associated with benign prostatic hyperplasia].
    Matsumoto S; Uemura H
    Hinyokika Kiyo; 2008 Jun; 54(6):453-6. PubMed ID: 18634445
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of tamsulosin on bladder blood flow and bladder function in rats with bladder outlet obstruction.
    Okutsu H; Matsumoto S; Hanai T; Noguchi Y; Fujiyasu N; Ohtake A; Suzuki M; Sato S; Sasamata M; Uemura H; Kurita T
    Urology; 2010 Jan; 75(1):235-40. PubMed ID: 19647304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of tamsulosin on bladder microcirculation in rat model of bladder outlet obstruction using pencil lens charge-coupled device microscopy system.
    Mine S; Yamamoto T; Mizuno H; Endo K; Matsukawa Y; Funahashi Y; Kato M; Hattori R; Gotoh M
    Urology; 2013 Jan; 81(1):155-9. PubMed ID: 23200970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decrease of ultrasound estimated bladder weight during tamsulosin treatment in patients with benign prostatic enlargement.
    Sironi D; Levorato CA; Deiana G; Borgonovo G; Belussi D; Ranieri A; Lembo A
    Arch Ital Urol Androl; 2002 Jun; 74(2):90-4. PubMed ID: 12161944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of tamsulosin with alfuzosin in the treatment of patients with lower urinary tract symptoms suggestive of bladder outlet obstruction (symptomatic benign prostatic hyperplasia). The European Tamsulosin Study Group.
    Buzelin JM; Fonteyne E; Kontturi M; Witjes WP; Khan A
    Br J Urol; 1997 Oct; 80(4):597-605. PubMed ID: 9352699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Latest frontiers in pharmacotherapy for benign prostatic hyperplasia].
    Kawabe K
    Yakugaku Zasshi; 2006 Mar; 126 Spec no.():199-206. PubMed ID: 16518083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of vibegron, a novel β
    Maruyama I; Yamamoto S; Tsuchioka K; Yamazaki T
    Eur J Pharmacol; 2020 Jul; 878():173096. PubMed ID: 32259514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial.
    Kaplan SA; Roehrborn CG; Rovner ES; Carlsson M; Bavendam T; Guan Z
    JAMA; 2006 Nov; 296(19):2319-28. PubMed ID: 17105794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized controlled study of the efficacy of tamsulosin monotherapy and its combination with mirabegron for overactive bladder induced by benign prostatic obstruction.
    Ichihara K; Masumori N; Fukuta F; Tsukamoto T; Iwasawa A; Tanaka Y
    J Urol; 2015 Mar; 193(3):921-6. PubMed ID: 25254938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of two alpha1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study.
    Nishino Y; Masue T; Miwa K; Takahashi Y; Ishihara S; Deguchi T
    BJU Int; 2006 Apr; 97(4):747-51, discussion 751. PubMed ID: 16536766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tamsulosin for benign prostatic hyperplasia.
    Wilt TJ; Mac Donald R; Rutks I
    Cochrane Database Syst Rev; 2003; (1):CD002081. PubMed ID: 12535426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical efficacy and safety of imidafenacin as add-on treatment for persistent overactive bladder symptoms despite α-blocker treatment in patients with BPH: the ADDITION study.
    Takeda M; Nishizawa O; Gotoh M; Yoshida M; Takahashi S; Masumori N
    Urology; 2013 Oct; 82(4):887-93. PubMed ID: 23953605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of the combination of an alpha1-blocker with an anticholinergic agent in the treatment of lower urinary tract symptoms associated with bladder outlet obstruction.
    Athanasopoulos A; Perimenis P
    Expert Opin Pharmacother; 2005 Nov; 6(14):2429-33. PubMed ID: 16259574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased contractile response to phenylephrine in detrusor of patients with bladder outlet obstruction: effect of the alpha1A and alpha1D-adrenergic receptor antagonist tamsulosin.
    Bouchelouche K; Andersen L; Alvarez S; Nordling J; Bouchelouche P
    J Urol; 2005 Feb; 173(2):657-61. PubMed ID: 15643283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tamsulosin for the treatment of benign prostatic hypertrophy.
    Lee M
    Ann Pharmacother; 2000 Feb; 34(2):188-99. PubMed ID: 10676828
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical comparison of selective and non-selective alpha 1A-adrenoceptor antagonists for bladder outlet obstruction associated with benign prostatic hyperplasia: studies on tamsulosin and terazosin in Chinese patients. The Chinese Tamsulosin Study Group.
    Na YJ; Guo YL; Gu FL
    J Med; 1998; 29(5-6):289-304. PubMed ID: 10503165
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of dutasteride, tamsulosin, and the combination on storage and voiding in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the Combination of Avodart and Tamsulosin study.
    Becher E; Roehrborn CG; Siami P; Gagnier RP; Wilson TH; Montorsi F
    Prostate Cancer Prostatic Dis; 2009; 12(4):369-74. PubMed ID: 19901936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Initial Use of High-Dose Anticholinergics Combined with Alpha-Blockers for Male Lower Urinary Tract Symptoms with Overactive Bladder: A Prospective, Randomized Preliminary Study.
    Lee KW; Hur KJ; Kim SH; Cho SY; Bae SR; Park BH; Lee YS; Han CH; Kim HW
    Low Urin Tract Symptoms; 2017 Sep; 9(3):129-133. PubMed ID: 27028190
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic effect of TAC-302, a cyclohexenoic fatty alcohol derivative, on bladder denervation-related storage and voiding dysfunctions in rats.
    Yoshida S; Noma T; Miyoshi K; Tsukihara H; Orimoto N; Hakozaki A; Sasaki E
    Neurourol Urodyn; 2018 Sep; 37(7):2106-2113. PubMed ID: 29635706
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score.
    Kaplan SA; Roehrborn CG; Chancellor M; Carlsson M; Bavendam T; Guan Z
    BJU Int; 2008 Nov; 102(9):1133-9. PubMed ID: 18510659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.